1334P Real word experience with first-line immunotherapy in advanced non-small cell lung cancer patients in a Danish nationwide cohort

Autor: E.B. Kristensen, Jessica Larsen, A.W. Moelby Nielsen, P.H. Homann, M. Boegsted, Andreas Carus, Karin Holmskov Hansen, Peter Meldgaard, Charlotte Kristiansen, B. Bjoernhart, Mette Thune Mouritzen, Morten Ladekarl, Charles Vesteghem, Gitte F. Persson, A-C. Bareid-Oestby, Kim Wedervang, Malene Støchkel Frank, M. Poehl

Publikováno v: Annals of Oncology. 31:S858

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::fcbead73d31dbcc0efc1e465d0635f83
https://doi.org/10.1016/j.annonc.2020.08.1648

Nationwide Survival Benefit after Implementation of First-Line Immunotherapy for Patients with Advanced NSCLC—Real World Efficacy

Autor: Seppo W. Langer, Heidi Christensen, Mette Thune Mouritzen, Charlotte Kristiansen, Lars B. Drivsholm, Anne Cathrine Østby, Jens Benn Sørensen, Kim Wedervang, Gitte F. Persson, Mette Pøhl, Jakob Lauritsen, Jon L. Andersen, Karin H. Hansen, Jacob W. Larsen, Birgitte Bjørnhart, Tine Schytte, Johanna M.C. Frary, Anders Winther Moelby Nielsen, Anna Emilie Livbjerg, Peter Meldgaard, Charles Vesteghem, Andreas Carus, Halla Skuladottir, Malene Støchkel Frank, Morten Ladekarl

Publikováno v: Aalborg University
Cancers
Volume 13
Issue 19
Mouritzen, M T, Carus, A, Ladekarl, M, Meldgaard, P, Nielsen, A W M, Livbjerg, A, Larsen, J W, Skuladottir, H, Kristiansen, C, Wedervang, K, Schytte, T, Hansen, K H, Østby, A-C, Frank, M S, Lauritsen, J, Sørensen, J B, Langer, S W, Persson, G F, Andersen, J L, Frary, J M C, Drivsholm, L B, Vesteghem, C, Christensen, H S, Bjørnhart, B & Pøhl, M 2021, ' Nationwide Survival Benefit after Implementation of First-Line Immunotherapy for Patients with Advanced NSCLC—Real World Efficacy ', Cancers, vol. 13, no. 19, 4846 . https://doi.org/10.3390/cancers13194846
Mouritzen, M T, Carus, A, Ladekarl, M, Meldgaard, P, Nielsen, A W M, Livbjerg, A, Larsen, J W, Skuladottir, H, Kristiansen, C, Wedervang, K, Schytte, T, Hansen, K H, Østby, A C, Frank, M S, Lauritsen, J, Sørensen, J B, Langer, S W, Persson, G F, Andersen, J L, Frary, J M C, Drivsholm, L B, Vesteghem, C, Christensen, H S, Bjørnhart, B & Pøhl, M 2021, ' Nationwide survival benefit after implementation of first-line immunotherapy for patients with advanced nsclc—real world efficacy ', Cancers, vol. 13, no. 19, 4846 . https://doi.org/10.3390/cancers13194846
Mouritzen, M T, Carus, A, Ladekarl, M, Meldgaard, P, Nielsen, A W M, Livbjerg, A, Larsen, J W, Skuladottir, H, Kristiansen, C, Wedervang, K, Schytte, T, Hansen, K H, Østby, A-C, Frank, M S, Lauritsen, J, Sørensen, J B, Langer, S W, Persson, G F, Andersen, J L, Frary, J M C, Drivsholm, L B, Vesteghem, C, Christensen, H S, Bjørnhart, B & Pøhl, M 2021, ' Nationwide Survival Benefit after Implementation of First-Line Immunotherapy for Patients with Advanced NSCLC—Real World Efficacy ', Klinisk Kvalitetskonference 2021, Aalborg, Denmark, 02/11/2021-03/11/2021 .
Cancers, Vol 13, Iss 4846, p 4846 (2021)

Simple Summary The expected change in overall survival (OS) in patients with advanced non-small cell lung cancer (NSCLC) after the clinical implementation of immune checkpoint inhibitor therapy (ICI) has not been substantially investigated in large r

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::d0fe8536813c8ff4aeae0919b920f7c8
https://vbn.aau.dk/en/publications/c85ef2ef-e87d-412d-b6e6-3802f565c001

Antineoplastic agents to cancer patients near end-of-life

Autor: Charles Vesteghem, Rasmus Brøndum, Mette Thune Mouritzen, Thomas Mulvad Larsen, Martin Bøgsted, Ursula Falkmer

Publikováno v: Aalborg University

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=dedup_wf_001::00a5018c31372f365d418b72d7ba15b5
https://vbn.aau.dk/en/publications/3517fb17-401f-42e1-9f55-ad1a7c2a1f72